Summary: In adults with infected diabetic foot ulcers requiring microbiological sampling, tissue sampling to identify causative pathogens through biopsy or debridement demonstrated no clear evidence of superior healing outcomes and was associated with higher costs and lower quality-adjusted life years (QALYs) compared to swab sampling as a less invasive alternative, with trial recruitment challenges during COVID-19 pandemic introducing uncertainty in findings.
| PICO | Description |
|---|---|
| Population | Adults with infected diabetic foot ulcers requiring microbiological sampling for wound management. |
| Intervention | Tissue sampling of infected diabetic foot ulcers to identify causative pathogens through biopsy or debridement. |
| Comparison | Swab sampling of infected diabetic foot ulcers as a less invasive alternative to tissue samples. |
| Outcome | Tissue sampling was more costly and associated with lower quality-adjusted life years (QALYs) compared to swabbing, with no clear evidence of superior healing outcomes. Trial recruitment challenges during COVID-19 pandemic introduced uncertainty. |
Clinical Context
Diabetic foot ulcers (DFUs) affect 15-25% of people with diabetes during their lifetime and are the leading cause of non-traumatic lower limb amputation. When DFUs become infected, appropriate antibiotic therapy is critical for healing and limb salvage. Accurate identification of causative pathogens guides antibiotic selection.
Two primary sampling approaches exist: swab cultures and tissue sampling. The theoretical argument for tissue sampling is compelling: swabs may only capture surface colonizers rather than the bacteria actually causing deep tissue infection. Tissue biopsies theoretically provide more accurate representation of true pathogens.
However, tissue sampling is more invasive, costly, and requires surgical skills. The CODIFI2 trial directly compared these approaches to determine whether the theoretical superiority of tissue sampling translates into better patient outcomes.
Clinical Pearls
1. Theory Doesn’t Always Translate to Outcomes: Despite the compelling microbiological rationale for tissue sampling, this trial found no healing advantage over swabs. Clinical outcomes—not microbiological purity—should guide practice decisions.
2. Swabs May Be Cost-Effective Standard of Care: Lower costs and similar (or possibly better) quality-adjusted life years with swab sampling suggests this simpler approach may be the economically rational choice for routine infected DFUs.
3. Lower QALYs with Tissue Sampling Raises Concerns: This unexpected finding may reflect discomfort from the biopsy procedure, wound healing issues at the biopsy site, or delays in treatment initiation while awaiting results.
4. COVID-19 Pandemic Limitations: Results should be interpreted with appropriate uncertainty due to severe recruitment challenges. Effect estimates have wide confidence intervals.
Practical Application
For most infected diabetic foot ulcers, swab sampling appears sufficient and may be preferred given lower costs and comparable outcomes. Use proper swab technique: debride surface debris and necrotic tissue first, then firmly rotate the swab over the clean wound base to capture tissue fluid.
Consider tissue sampling selectively for deep infections extending to bone or joint, chronic wounds with heavy polymicrobial colonization obscuring true pathogens, infections failing appropriate antibiotic therapy based on swab results, or when anaerobic pathogens are suspected but not captured by swab culture.
Broader Evidence Context
CODIFI2 is one of the first randomized trials to assess patient-centered outcomes of sampling methods rather than just microbiological endpoints. Previous studies compared pathogen detection rates but rarely followed patients to assess healing. These findings may prompt guideline revision.
The study aligns with broader trends toward pragmatic trials evaluating clinical outcomes rather than surrogate endpoints. Real-world effectiveness may differ substantially from theoretical advantages.
Study Limitations
The COVID-19 pandemic severely impacted recruitment, resulting in smaller sample size than planned. Uncertainty in outcome estimates is substantial. Long-term outcomes including amputation rates were not fully captured. Generalizability to non-pandemic conditions uncertain.
Bottom Line
Swab sampling for infected diabetic foot ulcers appears comparable to tissue sampling for clinical outcomes and is more cost-effective. For routine clinical practice, swab cultures are likely sufficient for guiding antibiotic therapy, with tissue sampling reserved for select complex cases.
Source: Nelson EA, et al. “Swabs versus tissue samples for infected diabetic foot ulcers: the CODIFI2 RCT.” Read article.
